Natera, Inc. announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includes more than 1,700 patients across 30+ sites, representing leading academic and private nephrology clinics in the U.S. A publication for the RenaCARE study is expected to be submitted in early 2023.

The RenaCARE study aims to demonstrate how genetic findings impact the clinical management of patient care and examines outcomes of patients tested with the Renasight genetic testing panel. It will also assess patient satisfaction, health knowledge and genetic literacy. The study follows a 2019 publication in The New England Journal of Medicine showing that approximately 10% of people with chronic kidney disease (CKD) have a genetic diagnosis.